Lonza expands cell-biology platform by acquiring Simbiosys Biowares’ preclinical cell and molecular biology group

15-Oct-2009

Lonza Group announces that it has completed the acquisition of the preclinical cell and molecular biology assets of Simbiosys Biowares India Pvt. Ltd as of 13 October 2009. Simbiosys Biowares is a premier biology outsourcing company with core competencies in cell and molecular biology, and in clinical services. The company’s cell and molecular biology group specializes in primary cell isolation and tissue sourcing and in performing preclinical services to mid-size pharmaceutical companies. Simbiosys Biowares India Pvt. Ltd. is based in Bangalore, India, with approximately 40 employees, and is a subsidiary of Simbiosys Biowares Inc., a start-up company based in Dallas, Texas, USA.

“We are happy to acquire the preclinical cell and molecular biology group of Simbiosys Biowares India, as it is aligned with Lonza’s strategy to continue to develop its life-science platform and to expand its global cell-biology portfolio. The deal further strengthens Lonza’s position as a worldwide leader in cell discovery by integrating a unique service model into its portfolio and by continuing to develop the company’s activities”, comments Anja Fiedler, Head of Lonza Bioscience. “The skilled R&D staff nicely complements our existing R&D capabilities in Cell Discovery”.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances